SLS Stock Jumps Ahead Of CEO’s Fox Appearance: Retail Bets AML Readout Could Spark Big Pharma Bidding War
July 20, 2026 · High impact · Updated Jul 21, 2026
SLS stock experienced a significant jump in anticipation of its CEO's appearance on Fox, driven by retail investor speculation that a positive AML (Acute Myeloid Leukemia) readout could lead to a bidding war among major pharmaceutical companies. Investors are specifically eyeing potential acquisition interest from industry giants like Johnson & Johnson, Merck, Pfizer, AbbVie, Eli Lilly, and Bristol Myers.
Affected Companies
Affected Industries
AlphaOS aggregates and analyzes market news to extract structured investment intelligence. Content is for research and education only — not investment advice.